Angitia Biopharmaceuticals
Angitia Biopharmaceuticals develops clinical-stage biologic therapies aimed at addressing serious musculoskeletal diseases through scientific research and regulatory-guided trials. The company studies product candidates such as AGA2118 for bone density issues, AGA2115 for connective tissue disorders, and AGA111 for bone fusion, advancing each through controlled clinical development. It operates a pipeline that integrates biologic drug research with data from human and preclinical studies to support regulatory progression and therapeutic evaluation. Angitia Biopharmaceuticals engages with medical and scientific communities to share clinical data and refine development strategies. The organization focuses on drug discovery and development processes that respond to defined clinical needs in musculoskeletal health.
Domain
angitiabio.com
Country
United StatesIndustry
BiopharmaEmployees
51-100
Last Funding
$130.0M
Founded
2017
Tech Stack (8 technologies)
Frequently Asked Questions
What technologies does Angitia Biopharmaceuticals use?+
Angitia Biopharmaceuticals uses 8 technologies including ScrollMagic, Swiper, GSAP.
What industry is Angitia Biopharmaceuticals in?+
Angitia Biopharmaceuticals operates in the Biopharma industry.
Where is Angitia Biopharmaceuticals based?+
Angitia Biopharmaceuticals is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026